Please assess the completion status of the following clinical trial:

Trial Title: Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Given written informed consent prior to any trial-related activity is performed~* Aged 55-75 years~* Mean number of nocturnal voids of at least two per night~* Reached post-menopause (applicable to females only)~Exclusion Criteria:~* Evidence of bladder outlet obstruction (BOO); or a urine flow of less than 5 mL/s (applicable to males only)~* A surgical treatment for BOO or prostatic hyperplasia within the past 6 months (applicable to males only)~* Showing symptoms of any of the following diseases and having a mean number of nocturnal voids exceeding four per night: Benign prostatic hyperplasia, overactive bladder, interstitial cystitis, severe stress urinary incontinence~* Psychosomatic or habitual polydipsia~* Urinary retention; or a post void residual volume in excess of 150 mL~* A history or complication of urologic malignancy (e.g. bladder cancer or prostate cancer)~* Complication of genito-urinary pathology (e.g. infection, stone, or neoplasia)~* Complication of neurogenic detrusor activity~* Complication or suspicion of heart failure~* Uncontrolled hypertension~* Uncontrolled diabetes mellitus~* Complication of hepatobiliary disease~* Abnormal serum creatinine level~* Complication of hyponatraemia, or serum sodium level \<135 mEq/L~* Central or nephrogenic diabetes insipidus (CDI or NDI)~* Syndrome of inappropriate antidiuretic hormone (SIADH)~* Obstructive sleep apnea~* Alcohol dependency or drug abuse~* A job or lifestyle that may interfere with regular night-time sleep~* Previous desmopressin treatment~* Treatment with another investigational product within the past 3 months~* A need for treatment with a prohibited concomitant drug for a complication or other problem~* A mental condition, the lack of decision-making ability, dementia or a speech handicap~* Any other reason that the Investigator believes inappropriate

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Desmopressin 10µg (Type: EXPERIMENTAL): Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.
- Desmopressin 25µg (Type: EXPERIMENTAL): Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.
- Desmopressin 50µg (Type: EXPERIMENTAL): Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.
- Desmopressin 100µg (Type: EXPERIMENTAL): Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.
- Placebo (Type: PLACEBO_COMPARATOR): Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).